REP-2055
- Generic Name
- REP-2055
Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B
Phase 2
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2016-04-04
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- Replicor Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT02726789
Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients
- First Posted Date
- 2016-01-05
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Replicor Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT02646163
- Locations
- 🇧🇩
Farabi General Hospital, Dhaka, Bangladesh
Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients
Phase 1
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2016-01-05
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Replicor Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02646189
- Locations
- 🇧🇩
Farabi General Hospital, Dhaka, Bangladesh
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath